European Pharmaceutical Review

NOVEMBER 11, 2022

A paper, published in the European Journal of Pharmaceutical Sciences identified the quality assurance (QA) challenges and trends of analytical techniques in ocular drug delivery and formulation, focusing on treatments for glaucoma. al focuses on formulations using substances such as prostaglandin F2 alpha (PGF2?) for latanoprost.”

Pharmaceutical 91

Pharmaceutical Safety Medicine 91

Pharmaceutical Technology

APRIL 20, 2023

In the first phase of its training workshops, the Pharmaceutical Innovation Center plans to develop a range of excipients [inactive substances that serve as the vehicle or medium for a drug or other active substance] for controlled release dosage forms, improving their bioavailability, along with formulating orally dispersible and chewable tablets.

Pharmaceutical 52

Pharmaceutical Training Manufacturing Pharma 52

European Pharmaceutical Review

DECEMBER 20, 2023

analysis (Source: L.E.K) Stakeholder reaction to original EC proposals suggests that changes are considered more favourable for generic/biosimilar manufacturers, given reduced RDP periods could lead to earlier generic/biosimilar entry for both non-orphan and orphan drugs ( see Figure 2 ). What are the latest amendments?

Biopharma 84

Biopharma Pharmaceutical Medicine Manufacturing 84

Pharmaceutical Technology

MAY 10, 2023

Particle analysis on a micro-scale is a significant topic in several fields of application. Within the pharmaceutical industry, it is critical to measure particle size as it influences surface area and porosity, impacting a drug’s bioavailability, effectiveness, and shelf life.

Pharmaceutical 52

Pharmaceutical Specialization Electronics 52

Clarivate

MAY 6, 2022

The analysis is led by David Pendlebury , Head of Research Analysis, and myself, Ryan Fry, Senior Product Data Analyst. The third Sustainable Development Goal, Good Health and Well-Being, covers a wide variety of topics. strengthening the prevention and treatment of substance abuse. What is a Highly Cited Researcher?

Education 98

Education Medicine Training Government 98

Pharmaceutical Technology

JUNE 13, 2023

The US Food and Drug Administration (FDA) approved Ferring Pharmaceuticals’ Prior-Approval Supplement (PAS) to the Biologics License Application (BLA) for the bladder cancer gene-therapy Adstiladrin (nadofaragene firadenovec). Topic sponsors are not involved in the creation of editorial content.

Manufacturing 98

Manufacturing FDA Food and Drug Administration Pharmaceutical 98

Pharmaceutical Technology

JANUARY 6, 2023

It is important for a CDMO to understand the market it serves and, in the dermatologic arena, that means the demand for topical agents across a broad array of indications. At Cambrex, quality comes first, and the same expectations for quality apply equally to prescription and OTC topical products. Simplicity matters. an antibiotic).

Manufacturing 52

Manufacturing Food and Drug Administration Prescription Distribution 52